SOLO2: Safety, HRQoL With Maintenance Olaparib in Germline BRCA-Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer

June 2-6, 2017; Chicago, Illinois
No detrimental effect on HRQoL, significant improvement in patient-centered benefits with olaparib vs placebo despite higher olaparib-associated toxicity.
Format: Microsoft PowerPoint (.ppt)
File Size: 577 KB
Released: June 13, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Downloadable slideset on the latest clinical data on the management of endometrial cancer, from Clinical Care Options (CCO)

person default Linda R. Duska, MD, MPH Released: June 18, 2021

Phase III OUTBACK study of standard chemoradiation ± adjuvant chemotherapy in locally advanced cervical cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 11, 2021

Randomized TOTEM trial of intensive vs minimalist follow-up in patients treated for endometrial cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Phase III trial of pafolacianine sodium injection plus fluorescent imaging for resection of ovarian cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue